Primary cutaneous immunocytoma/marginal zone B-cell lymphoma: a case with unusual course.
Although primary cutaneous immunocytoma/marginal zone B-cell lymphoma (PCI/MZBL) is considered as an indolent lymphoma with excellent prognosis, extracutaneous spread and even death due to disseminated disease have been reported. This is a case report of a PCI/MZBL showing dissemination to the regional lymph node and bone marrow, 22 months after the initial diagnosis. Furthermore, in the lymph node, there were focal areas of high-grade transformation. On the other hand, the bone marrow involvement displayed low-grade morphology. We suggest that it should be kept in mind that there is still a possibility of systemic involvement in PCI/MZBL.
Demirkesen
Cuyan
C
Department of Pathology, Cerrahpasça Medical Faculty, University of Istanbul, Istanbul, Turkey. odemirkesen@ixir.com
Tüzüner
Nükhet
N
Su
Ozlem
O
Eskazan
Ahmet Emre
AE
Esçkazan
Ahmet Emre
AE
Soysal
Teoman
T
Onsun
Nahide
N
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology*; D002471:Cell Transformation, Neoplastic; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008198:Lymph Nodes / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction; D012878:Skin Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins